Primary antibodies LC3A/B (1:1000 dilution, #4108, Cell Signaling Technology, Massachusetts, United States), p62 (1:2000 dilution, ab56416, Abcam, Massachusetts, United States), PINK1 (1:1000 dilution, 23274-1-AP, Proteintech Group, Illinois, United States), and Parkin (1:1000 dilution, ab15954, Abcam, Massachusetts, United States) were used to incubate tissue sections overnight at 4C
Every clinical trial protocol started all participants at 1mg weekly, regardless of their target maintenance dose
Science 356 , eaal3321 (2017)
The bigger outcome is that this study needs to be conducted on a larger scale
What to Do if You Hit a Plateau on a GLP-1 Using a GLP-1 but stuck at a plateau
Notably, the simultaneous use of both pharmacological classes provided a significantly greater benefit in outcomes such as mortality, hospitalizations, heart failure, and CKD ( Building on the findings of the aforementioned trials, several meta-analyses have been conducted since 2019 to evaluate the safety and efficacy of combining GLP-1 RAs and SGLT-2 inhibitors
